STOCK TITAN

Column Group funds trim Tenaya Therapeutics (TNYA) with 829,734-share sale

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Column Group–affiliated investment funds, significant stockholders of Tenaya Therapeutics, reported open-market sales of an aggregate 829,734 shares of Common Stock on February 20 and 23. Reported weighted-average sale prices were about $0.61 per share, within disclosed ranges from $0.573 to $0.63.

The securities are held indirectly through entities including The Column Group III, LP, The Column Group III-A, LP and TCG Opportunity III LPPeter Svennilson and Tim Kutzkey, may be deemed to share voting and investment power but disclaim beneficial ownership except to the extent of their pecuniary interest.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
COLUMN GROUP III GP, LP

(Last) (First) (Middle)
1 LETTERMAN DR
BLDG. D, STE. DM-900

(Street)
SAN FRANCISCO CA 94129

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/20/2026 S 245,965 D $0.6149(1) 2,102,218 I See Footnote(2)
Common Stock 02/20/2026 S 277,769 D $0.6149(1) 2,374,048 I See Footnote(3)
Common Stock 02/23/2026 S 143,709 D $0.5972(4) 1,958,509 I See Footnote(2)
Common Stock 02/23/2026 S 162,291 D $0.5972(4) 2,211,757 I See Footnote(3)
Common Stock 49,313,559 I See Footnote(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
COLUMN GROUP III GP, LP

(Last) (First) (Middle)
1 LETTERMAN DR
BLDG. D, STE. DM-900

(Street)
SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
COLUMN GROUP III, LP

(Last) (First) (Middle)
1 LETTERMAN DRIVE
BLDG. D, STE DM-900

(Street)
SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
COLUMN GROUP III-A, LP

(Last) (First) (Middle)
1 LETTERMAN DR
BLDG. D, STE, DM-900

(Street)
SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Column Group Opportunity III, LP

(Last) (First) (Middle)
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900

(Street)
SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Column Group Opportunity III GP, LP

(Last) (First) (Middle)
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900

(Street)
SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
TCG Opportunity III GP, LLC

(Last) (First) (Middle)
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900

(Street)
SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Kutzkey Tim

(Last) (First) (Middle)
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900

(Street)
SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Svennilson Peter

(Last) (First) (Middle)
1 LETTERMAN DRIVE
BUILDING D, SUITE DM-900

(Street)
SAN FRANCISCO CA 94129

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.60 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
2. The securities are directly held by The Column Group III, LP ("TCG III LP"). TCG III GP is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are Peter Svennilson and Tim Kutzkey (together, the "Managing Partners"). The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
3. The securities are directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such shares. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.573 to $0.6225, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
5. The securities are directly held by TCG Opportunity III LP. The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are the Managing Partners. The Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
The Column Group III GP, LP /s/James Evangelista, Attorney-in-Fact 02/24/2026
The Column Group III, LP by The Column Group III GP, LP, its general partner /s/ James Evangelista Attorney-in-Fact 02/24/2026
The Column Group III-A, LP. by The Column Group III GP, LP, its general partner /s/ James Evangelista Attorney-in-Fact 02/24/2026
/s/ James Evangelista, as Attorney-in-Fact for The Column Group Opportunity III LP 02/24/2026
/s/ James Evangelista, as Attorney-in-Fact for The Column Group Opportunity III GP LP 02/24/2026
/s/ James Evangelista, as Attorney-in-Fact for TCG Opportunity III GP, LLC 02/24/2026
/s/ James Evangelista, as Attorney-in-Fact for Tim Kutzkey 02/24/2026
/s/ James Evangelista, as Attorney-in-Fact for Peter Svennilson 02/24/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Column Group entities report for Tenaya Therapeutics (TNYA)?

Column Group–affiliated funds reported selling 829,734 shares of Tenaya Therapeutics common stock in open-market transactions on February 20 and 23, 2026. All reported positions are held indirectly through investment partnerships described in the filing’s footnotes.

At what prices did the Column Group funds sell TNYA shares?

The reported weighted-average sale prices were about $0.61 per TNYA share. Footnotes explain that individual trades occurred at prices ranging from $0.573 to $0.6225 and from $0.60 to $0.63 per share during the reported trading days.

How many Tenaya Therapeutics (TNYA) shares did Column Group entities sell in total?

The filing shows total net sales of 829,734 TNYA common shares across four open-market transactions. Individual trades within those transactions were executed at various prices within the disclosed ranges in the footnotes to the Form 4.

Who actually holds the Tenaya Therapeutics (TNYA) shares reported in this Form 4?

The shares are directly held by investment partnerships, including The Column Group III, LP, The Column Group III-A, LP and TCG Opportunity III LP. Related general partners and managing partners may be deemed to share voting power as described in the detailed ownership footnotes.

Do the individual managers personally own the TNYA shares reported in this filing?

The footnotes state that managing partners, including Peter Svennilson and Tim Kutzkey, may be deemed to share voting and investment power. However, they and certain general partners disclaim beneficial ownership except to the extent of their respective pecuniary interests in the securities.

What does the weighted-average sale price disclosure mean for TNYA trades?

Weighted-average prices indicate that each reported transaction includes multiple individual trades at different prices within stated ranges. The reporting persons commit to provide full breakdowns of share counts at each specific price upon request to the issuer, security holders or SEC staff.
Tenaya Therapeutics, Inc.

NASDAQ:TNYA

TNYA Rankings

TNYA Latest News

TNYA Latest SEC Filings

TNYA Stock Data

130.34M
214.85M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
SOUTH SAN FRANCISCO